Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?

Anti-Cancer Drugs

Volumn 15, Issue 9, 2004, Pages 871-875

  Lau, Derick ^a   Guo, Linlang ^a   Gandara, David ^a   Young, Lawrence J T ^a   Xue, Ling ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Antiangiogenesis; Dosing schedules; Paclitaxel

Indexed keywords

PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; FEMALE; LEUKOCYTE COUNT; LOW DRUG DOSE; LUNG CANCER; MICROVASCULATURE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; FEMALE; GROWTH INHIBITORS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 8344227715     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200410000-00007     Document Type: Article

References (23)

1. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al. Phase III trial of doxorubicln, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21:588-592.
2. Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-3218.
3. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21:2460-2465.
4. DeVore RF, Jagasia M, Johnson D. Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: preliminary results comparing sequential phase II trials. Semin Oncol 1997; 24(suppl):27-29.
5. Akerly W, Sikov WM, Cummings F, Safran H, Strenger R, Marchant D. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. Semin Oncol 1997; 24(suppl):87-90.
6. Chang AY, Boros L, Asbury R, Hui L, Rubins J. Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer. Semin Oncol 1997; 24(suppl):69-71.
7. Browder T, Butterfield CE, Kraaling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878-1886.
8. Ukena D, Schroeder M, Dittrich I, Guschall WR, Ko YD, Saar T, et al. Phase III randomized trial comparing paclitaxel/carboplatin every 3 weeks with weekly paclitaxel/carboplatin in patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:623.
9. Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003; 21:2933-2939.
10. Goble S, Bear HD. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Surg Clin North Am 2003; 83:943-971.
11. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 22:665-667.
12. Rowinsky EK, Donnehower RC, Jones RJ. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988; 48:4093-4100.
13. Belotti D, Nicoletti I, Vergani V, Rieppi M, Drudis T, Viale G, et al. Paclitaxel (Taxol), a microtubule affecting drug, inhibits tumor induced angiogenesis. Proc Am Ass Cancer Res 1996; 37:397.
14. Oktaba AMC, Hunter WL, Arsenault AL. Taxol: a potent inhibitor of normal and tumor-induced angiogenesis. Proc Am Ass Cancer Res 1995; 16:454.
15. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato R J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997; 57:81-86.
16. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999; 14:31-36.
17. Guo LL, Burke P, Lo SH, Gandour-Edwards R, Lau D. Quantitative analysis of angiogenesis using confocal laser microscopy. Angiogenesis 2001; 4:187-191.
18. Shi B, Yaremko B, Haijian G, Terracina G, Bishop WR, Liu M, et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 2000; 46:387-393.
19. Papadopoulou MV, Ji M, Ji X, Bloomer WD, Hollingshead MG. Therapeutic advantages from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice. Cancer Chemother Pharmacol 2002; 50:501-508.
20. Nguyen DM, Lorang D, Chen A, Stewart JH, Tabibi E, Schrump DS. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg 2001; 72:371-379.
21. Rowinsky EK. Clinical pharamacology of taxol. J Natl Cancer Inst Monogr 1993; 15:25-38.
22. Mohamed F, Marchettini P, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol 2003; 52:405-410.
23. Barker K. At the Bench. A Laboratory Navigator. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1998, pp. 225-226.